Rigel Pharmaceuticals, Inc. (RIGL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159975,
    "name": "Rigel Pharmaceuticals, Inc.",
    "stock_name": "Rigel Pharmaceuticals, Inc.",
    "full_name": "Rigel Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/rigel-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "47.38",
    "chg": 2.97,
    "chgp": "6.69%",
    "dir": 1,
    "prev_price": "44.41",
    "mcapval": "733.10",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US7665596034",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "790.57 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/rigel-pharmaceuticals-inc-1159975-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Rigel Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-rigel-pharmaceuticals-inc-technically-bullish-or-bearish-3545706",
        "imagepath": "",
        "date": "2025-09-20 19:16:42",
        "description": "As of 21 July 2025, the technical trend for Rigel Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, supporting a positive outlook. Daily moving averages are also bullish, while Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. However, the Dow Theory shows a mildly bearish signal on the weekly chart, which slightly tempers the overall bullish sentiment.\n\nIn terms of performance, Rigel Pharmaceuticals has significantly outperformed the S&P 500 over the past year, with a return of 157.59% compared to the S&P 500's 17.14%. Despite recent short-term declines, the longer-term trend remains strongly bullish...."
      },
      {
        "title": "Is Rigel Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-rigel-pharmaceuticals-inc-overvalued-or-undervalued-3542391",
        "imagepath": "",
        "date": "2025-09-20 17:51:43",
        "description": "As of 12 September 2025, Rigel Pharmaceuticals, Inc. has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, as indicated by its P/E ratio of 10, significantly lower than the industry average, and a PEG ratio of 0.01, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 7.92, further supporting the undervaluation thesis.\n\nIn comparison to its peers, Rigel Pharmaceuticals has a P/E of 7.49, while 2seventy Bio, Inc. shows a much higher P/E of 76.93, indicating that Rigel is trading at a substantial discount. Scilex Holding Co. also presents a negative P/E, highlighting the relative strength of Rigel's valuation metrics. Over the past year, Rigel has returned 157.59%, outperforming the S&P 500's 17.14%, which reinforces the attractiveness of its current valuation...."
      },
      {
        "title": "Rigel Pharmaceuticals Sees Valuation Upgrade Amid Strong Financial Performance and Growth",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/rigel-pharmaceuticals-upgraded-to-buy-as-valuation-grade-improves-significantly-3526033",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/RigelPharmaceut_mojoScore_3526033.png",
        "date": "2025-09-17 16:01:56",
        "description": "Rigel Pharmaceuticals, Inc. has experienced a significant evaluation adjustment, moving to a very attractive valuation grade. Key financial metrics include a P/E ratio of 10, a high Return on Capital Employed of 2630.60%, and impressive net profit growth of 420.82%, reflecting strong operational performance and stability."
      },
      {
        "title": "Rigel Pharmaceuticals Experiences Valuation Adjustment Amid Strong Financial Metrics and Market Position",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rigel-pharmaceuticals-changes-valuation-grade-from-attractive-to-very-attractive-3522690",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/RigelPharmaceut_valuationdot_3522690.png",
        "date": "2025-09-16 18:00:26",
        "description": "Rigel Pharmaceuticals, Inc. has adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 10 and a high return on capital employed at 2630.60%. Compared to peers, Rigel presents a more favorable valuation profile, with significant year-to-date and one-year returns outperforming the S&P 500."
      },
      {
        "title": "Rigel Pharmaceuticals Achieves 172.26% Return, Marking It as a Multibagger in Biotechnology Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rigel-pharmaceuticals-achieves-17226-return-marking-it-as-a-multibagger-in-biotechnology-sector-3520018",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/RigelPharmaceut_multibagger_3520018.png",
        "date": "2025-09-16 15:17:02",
        "description": "Rigel Pharmaceuticals, Inc. has recently undergone a revision in its score, reflecting its strong financial performance and market position. Despite a minor decline in stock price, the company has achieved remarkable year-to-date returns and impressive growth in net profit, underscoring its resilience and operational efficiency in the competitive pharmaceuticals sector."
      }
    ],
    "total": 10,
    "sid": "1159975",
    "stock_news_url": "https://www.marketsmojo.com/news/rigel-pharmaceuticals-inc-1159975"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Rigel Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:16:42

As of 21 July 2025, the technical trend for Rigel Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, supporting a positive outlook. Daily moving averages are also bullish, while Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. However, the Dow Theory shows a mildly bearish signal on the weekly chart, which slightly tempers the overall bullish sentiment. In terms of performance, Rigel Pharmaceuticals has significantly outperformed the S&P 500 over the past year, with a return of 157.59% compared to the S&P 500's 17.14%. Despite recent short-term declines, the longer-term trend remains strongly bullish....

Is Rigel Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 17:51:43

As of 12 September 2025, Rigel Pharmaceuticals, Inc. has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, as indicated by its P/E ratio of 10, significantly lower than the industry average, and a PEG ratio of 0.01, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 7.92, further supporting the undervaluation thesis. In comparison to its peers, Rigel Pharmaceuticals has a P/E of 7.49, while 2seventy Bio, Inc. shows a much higher P/E of 76.93, indicating that Rigel is trading at a substantial discount. Scilex Holding Co. also presents a negative P/E, highlighting the relative strength of Rigel's valuation metrics. Over the past year, Rigel has returned 157.59%, outperforming the S&P 500's 17.14%, which reinforces the attractiveness of its current valuation....

Rigel Pharmaceuticals Sees Valuation Upgrade Amid Strong Financial Performance and Growth

2025-09-17 16:01:56

Rigel Pharmaceuticals, Inc. has experienced a significant evaluation adjustment, moving to a very attractive valuation grade. Key financial metrics include a P/E ratio of 10, a high Return on Capital Employed of 2630.60%, and impressive net profit growth of 420.82%, reflecting strong operational performance and stability.

Rigel Pharmaceuticals Experiences Valuation Adjustment Amid Strong Financial Metrics and Market Position

2025-09-16 18:00:26

Rigel Pharmaceuticals, Inc. has adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 10 and a high return on capital employed at 2630.60%. Compared to peers, Rigel presents a more favorable valuation profile, with significant year-to-date and one-year returns outperforming the S&P 500.

Rigel Pharmaceuticals Achieves 172.26% Return, Marking It as a Multibagger in Biotechnology Sector

2025-09-16 15:17:02

Rigel Pharmaceuticals, Inc. has recently undergone a revision in its score, reflecting its strong financial performance and market position. Despite a minor decline in stock price, the company has achieved remarkable year-to-date returns and impressive growth in net profit, underscoring its resilience and operational efficiency in the competitive pharmaceuticals sector.

View All News